Remsima (infliximab) is a biologic medicine that helps the pain and swelling of arthritis. It works by blocking TNF (Tumor Necrosis Factor), a type of signalling protein (called a cytokine), that is involved in systemic inflammation. Remsima belongs to a class of similar medications called Anti-TNF agents.
Remsima is used in the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Colitis, Psoriasis, and other types of arthritis.
Remsima is a type of medicine that is called a biosimilar. A biosimilar is a new type of biologic medication that has been designed to be identical to an existing biologic medication, but created using a different process. Remsima is a biosimilar of Remicade. Both medications are known by the same generic name: infliximab. Biosimilars are often more cost effective than the medications that they replicate.
Important Tests and Risks
Remsima can make it a bit harder for people to fight off infections. Patients taking this medicine should call their doctor they have a fever, think they have an infection, or have been prescribed antibiotics to treat an infection.
Patients should coordinate with their doctor to stop treatment before any surgery, and re-start once things have healed and there’s no sign of infection.
Patients should discuss all vaccinations with their doctor because some are not advisable to receive while taking Remsima.
It is important to have a tuberculosis skin test done and get a chest x-ray before starting Remsima.
Patients who are taking Remsima should have occasional blood tests as requested by their doctor to keep track of their arthritis and make sure that blood counts are ok.
Drug Identification Number (DIN): 02419483 (IV)